#Obscure 2 small key locations hospital software

BAE was performed with a BAE system (Fujifilm, Saitama, Japan) using a Fujifilm EN-450T5, EN-530T, or EN-580T endoscope. BAE can be performed via oral and rectal approaches, depending on the CE findings. In patients with positive findings during CE, BAE was used to confirm and possibly treat the lesions. Lesion locations were reported by referring to the SBTT. The first recorded duodenal images and the first recorded cecal images were time-stamped, and the period between the two points was marked as small bowel transit time (SBTT).

#Obscure 2 small key locations hospital software

Images were analyzed with the RAPID Reader 6 software program on a RAPID 5 or 6.5 work station (Given Imaging Ltd.). Patients were instructed to swallow the CE capsule with dimethicone solution and wore the detection sensor and recording device for 8 hours. Four hours before the procedures, patients were required to take mannitol solution as standard bowel preparation.ĬE was performed using a video capsule endoscopy device (PillCam SB2, or SB3 Given Imaging Ltd., Yokneam, Israel). Patients undergoing either CE or BAE were required to fast overnight to clean the upper and lower GI tract. Patients with swallowing difficulties, suspected intestinal obstruction, cardiac pacemakers, or implantable electromedical devices were suggested to undergo balloon-assisted endoscopy (BAE) rather than CE. The aim of this study was to identify the risk factors associated with rebleeding rates in OGIB cases to make a contribution to the management of OGIB. In the present study, we investigated the clinical characteristics of OGIB patients from southern China and compared the characteristics between rebleeding cases and non-rebleeding cases. However, although important, the risk factors associated with rebleeding rates in OGIB cases are not yet fully understood. 9 found that rebleeding occurred in 9.5% of OGIB cases after therapeutic intervention, and in 40% of cases who did not undergo therapeutic intervention. 8 reported that the rebleeding rate in OGIB patients with positive CE findings reached 48.4%. 6, 7 Thanks to the availability of CE and BAE, the diagnosis and treatment of OGIB have improved greatly however, rebleeding remains a major challenge.

One type is overt bleeding, constituting patients with melena or hematochezia, and the other is occult bleeding, constituting patients without visible bleeding but with positive fecal occult blood test results. OGIB is generally categorized into two subtypes according to the American Journal of Gastroenterology Clinical Guideline. 3 The advent of small bowel capsule endoscopy (CE) and balloon-assisted endoscopy (BAE) has made detecting small bowel bleeding (SBB) possible. 2 Previous studies have suggested that the bleeding lesions in OGIB are usually located in the small bowel. 1 It has been estimated that OGIB accounts for approximately 5% of gastrointestinal (GI) bleeding cases.

Obscure gastrointestinal bleeding (OGIB) is defined as gastrointestinal bleeding of unknown origin with negative initial endoscopy (colonoscopy and esophagogastroduodenoscopy) results.